Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.…
Liminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price Rule
Liminatus Pharma (NASDAQ: LIMN) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 1 employees.
The shares were at 2.510 USD on 20 November 2026, up 124.1% over 52 weeks. Its 52-week range is 0.0952 USD to 7.050 USD: the price is 64.4% below the high and 2536.6% above the low.
Its market capitalisation is 3.37M USD.
Liminatus Pharma reports return on equity of 104.0% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 1.57M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.
No upcoming events tracked.